Article Details
Retrieved on: 2024-01-26 21:21:58
Tags for this article:
Click the tags to see associated articles and topics
Summary
ArriVent Biopharma, targeting Biopharma sector, notably lung cancer, has raised $175 million in its IPO to advance furmonertinib, an EGFR inhibitor for non-small-cell lung cancer, addressing oncogenic mutations like T790M.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here